Q32 Bio Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021
Period Ending	Sep '24 Sep 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	-14.66	-6.65	6.65	-
Cost of Revenue	45.94	31.73	35.81	29.93
Gross Profit	-60.6	-38.38	-29.16	-29.93
Selling, General & Admin	16.79	9.88	10.06	6.76
Operating Expenses	16.79	9.88	10.06	6.76
Operating Income	-77.39	-48.26	-39.23	-36.69
Interest Expense	-1.3	-0.5	-	-
Interest & Investment Income	4.2	1.2	-	-
Other Non Operating Income (Expenses)	16.45	-5.87	-3.52	-0.32
Pretax Income	-58.73	-53.43	-42.75	-37.02
Income Tax Expense	1.88	0.32	0.06	0.55
Net Income	-60.61	-53.74	-42.81	-37.56
Net Income to Common	-60.61	-53.74	-42.81	-37.56
Shares Outstanding (Basic)	13	7	7	6
Shares Outstanding (Diluted)	13	7	7	6
Shares Change (YoY)	548.42%	3.25%	8.57%	-
EPS (Basic)	-4.57	-7.41	-6.09	-5.81
EPS (Diluted)	-5.76	-7.41	-6.09	-5.81
Free Cash Flow	-67.07	-18.68	-13.44	-33.14
Free Cash Flow Per Share	-5.06	-2.58	-1.91	-5.12
Operating Margin	-	-	-589.76%	-
Profit Margin	-	-	-643.65%	-
Free Cash Flow Margin	-	-	-202.10%	-
EBITDA	-76.89	-47.76	-38.86	-36.65
D&A For EBITDA	0.49	0.5	0.37	0.05
EBIT	-77.39	-48.26	-39.23	-36.69

Source: S&P Capital IQ. Standard template. Financial Sources.